Literature DB >> 23361950

Use of thrombolysis in myocardial infarction risk score to predict bleeding complications in patients with unstable angina and non-ST elevation myocardial infarction undergoing percutaneous coronary intervention.

Yohei Numasawa1, Shun Kohsaka, Hiroaki Miyata, Akio Kawamura, Shigetaka Noma, Masahiro Suzuki, Susumu Nakagawa, Yukihiko Momiyama, Toshiyuki Takahashi, Yuji Sato, Keiichi Fukuda.   

Abstract

Thrombolysis in myocardial infarction (TIMI) is a prognostic score developed for managing the high risk of cardiac events immediately after unstable angina and non-ST elevation myocardial infarction (UA/NSTEMI). In Asian populations that have a higher rate of bleeding complications, data about TIMI score are lacking. Using a Japanese multicenter registry, we investigated the impact of utilizing TIMI score in UA/NSTEMI patients, focusing on bleeding complications. The TIMI score was calculated for 587 patients who underwent percutaneous coronary intervention (PCI) for UA/NSTEMI (2008-2010). They were classified into low-risk (TIMI score 0-2, N = 268, 45.6 %), intermediate-risk (TIMI score 3-4, N = 264, 45.0 %) and high-risk (TIMI score 5-7, N = 55, 9.4 %) groups; patient characteristics for each group were statistically analyzed. The patients in the higher TIMI score group were older (p < 0.001), had lower GFR (p = 0.021) and hemoglobin level after PCI (p < 0.001), and severe coronary disease pattern (p = 0.014 and p = 0.023, respectively, for left main and three-vessel disease). The TIMI score was significantly associated with requirement of blood transfusion (low-risk, moderate-risk, and high-risk groups: 1.1, 4.2, and 7.3 %, respectively; p = 0.021), and the incidence of access site bleeding (1.1, 2.7, and 5.5 %, p = 0.112). The TIMI score might aid in subjectively quantifying the risk of in-hospital complication rates such as access site bleeding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23361950     DOI: 10.1007/s12928-013-0162-3

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  5 in total

1.  Real-world use of intravascular ultrasound in Japan: a report from contemporary multicenter PCI registry.

Authors:  Toshiki Kuno; Yohei Numasawa; Mitsuaki Sawano; Takayuki Abe; Ikuko Ueda; Masaki Kodaira; Masahiro Suzuki; Shigetaka Noma; Iwao Nakamura; Koji Negishi; Shiro Ishikawa; Keiichi Fukuda; Shun Kohsaka
Journal:  Heart Vessels       Date:  2019-05-25       Impact factor: 2.037

2.  Gender differences in in-hospital clinical outcomes after percutaneous coronary interventions: an insight from a Japanese multicenter registry.

Authors:  Yohei Numasawa; Shun Kohsaka; Hiroaki Miyata; Shigetaka Noma; Masahiro Suzuki; Shiro Ishikawa; Iwao Nakamura; Yutaro Nishi; Takahiro Ohki; Koji Negishi; Toshiyuki Takahashi; Keiichi Fukuda
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

3.  Impact of coronary dominance on in-hospital outcomes after percutaneous coronary intervention in patients with acute coronary syndrome.

Authors:  Toshiki Kuno; Yohei Numasawa; Hiroaki Miyata; Toshiyuki Takahashi; Koichiro Sueyoshi; Takahiro Ohki; Koji Negishi; Akio Kawamura; Shun Kohsaka; Keiichi Fukuda
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

4.  Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry.

Authors:  Yohei Numasawa; Shun Kohsaka; Hiroaki Miyata; Akio Kawamura; Shigetaka Noma; Masahiro Suzuki; Susumu Nakagawa; Yukihiko Momiyama; Kotaro Naito; Keiichi Fukuda
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

5.  Financial burden of survivors of medically-managed myocardial infarction and its association with selected social determinants and quality of life in a lower middle income country.

Authors:  P K B Mahesh; M W Gunathunga; S Jayasinghe; S M Arnold; D S V Mallawarachchi; S K Perera; U A D Wijesinghe
Journal:  BMC Cardiovasc Disord       Date:  2017-09-19       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.